You just read:

Reportlinker Adds Musculoskeletal Disorders Therapeutics to 2016 - Introduction of Monoclonal Antibodies with First - in - class Mechanism of Action to Increase Treatment Options in Osteoporosis and Rheumatoid Arthritis

News provided by

Reportlinker

Oct 12, 2010, 07:41 ET